+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Next Generation Cancer Diagnostics Market Research Report by Technology, by Function, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 5311174
  • Report
  • June 2021
  • Region: Global
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Next Generation Cancer Diagnostics Market Grew USD 20,092.53 Million by 2026, at a CAGR of 23.38%

FEATURED COMPANIES

  • Abbott Laboratories
  • Akadeum Life Sciences
  • Becton, Dickinson And Co.
  • Danaher Corporation
  • GE Healthcare
  • Illumina, Inc.
The Global Next Generation Cancer Diagnostics Market size was estimated at USD 5,693.78 Million in 2020 and expected to reach USD 7,006.17 Million in 2021, at a Compound Annual Growth Rate (CAGR) 23.38% from 2020 to 2026 to reach USD 20,092.53 Million by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Next Generation Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Technology, the Next Generation Cancer Diagnostics Market was examined across DNA Microarrays, Lab-on- a- chip & Reverse Transcriptase-PCR, Next Generation Sequencing, Protein Microarrays, and qPCR & Multiplexing.
  • Based on Cancer Type, the Next Generation Cancer Diagnostics Market was examined across Breast Cancer, Cervical Cancer, Colorectal Cancer, and Lung Cancer.
  • Based on Function, the Next Generation Cancer Diagnostics Market was examined across Cancer Screening, Companion Diagnostics, Prognostics, Risk Analysis, and Therapeutic Monitoring.
  • Based on Application, the Next Generation Cancer Diagnostics Market was examined across Biomarker Development, CTC Analysis, Epigenetic Analysis, Genetic Analysis, and Proteomic Analysis.
  • Based on Geography, the Next Generation Cancer Diagnostics Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. The ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Next Generation Cancer Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Next Generation Cancer Diagnostics Market, including Abbott Laboratories, Adaptive Biotechnologies Inc., Agendia Nv, Agilent Technologies, Inc, Akadeum Life Sciences, Almac Group, Ambry Genetics, Becton, Dickinson And Co., Biological Dynamics Inc., Castle Biosciences Inc., Danaher Corporation, Exosome Diagnostics, Inc., F. Hoffmann-La Roche Ltd, GE Healthcare, Genomic Health, Inc., Hologic, Inc, Illumina, Inc., Janssen Global Services, LLC, Koninklijke Philips N.V., Myriad Genetics, Inc., Novartis AG, Opko Health, Inc., Perkin Elmer, Inc., Qiagen N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Next Generation Cancer Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Next Generation Cancer Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Next Generation Cancer Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Next Generation Cancer Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Next Generation Cancer Diagnostics Market?
6. What is the market share of the leading vendors in the Global Next Generation Cancer Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Next Generation Cancer Diagnostics Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Akadeum Life Sciences
  • Becton, Dickinson And Co.
  • Danaher Corporation
  • GE Healthcare
  • Illumina, Inc.
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Cancer Type Outlook
3.4. Technology Outlook
3.5. Function Outlook
3.6. Application Outlook
3.7. Geography Outlook
3.8. Competitor Outlook

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of oncology diseases
5.1.1.2. Significantly decreasing cost of genetic sequencing
5.1.1.3. Benefits of cluster chip technology and applications of CTC in cancer management
5.1.2. Restraints
5.1.2.1. Need for expensive laboratory set-up
5.1.2.2. Insufficient reimbursement policies for innovative technologies
5.1.3. Opportunities
5.1.3.1. Government support in a number of research projects in oncology and preventative diagnosis
5.1.3.2. Potential CTC enumeration sectors to monitor tumorigenesis
5.1.4. Challenges
5.1.4.1. Shortage of helium and increased cost of diagnostic imaging systems
5.2. Cumulative Impact of COVID-19
5.3. Porters Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry

6. Next Generation Cancer Diagnostics Market, by Technology
6.1. Introduction
6.2. DNA Microarrays
6.3. Lab-on- a- chip & Reverse Transcriptase-PCR
6.4. Next Generation Sequencing
6.5. Protein Microarrays
6.6. qPCR & Multiplexing

7. Next Generation Cancer Diagnostics Market, by Cancer Type
7.1. Introduction
7.2. Breast Cancer
7.3. Cervical Cancer
7.4. Colorectal Cancer
7.5. Lung Cancer

8. Next Generation Cancer Diagnostics Market, by Function
8.1. Introduction
8.2. Cancer Screening
8.3. Companion Diagnostics
8.4. Prognostics
8.5. Risk Analysis
8.6. Therapeutic Monitoring

9. Next Generation Cancer Diagnostics Market, by Application
9.1. Introduction
9.2. Biomarker Development
9.3. CTC Analysis
9.4. Epigenetic Analysis
9.5. Genetic Analysis
9.6. Proteomic Analysis

10. Americas Next Generation Cancer Diagnostics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
10.6.1. California
10.6.2. Florida
10.6.3. Illinois
10.6.4. New York
10.6.5. Ohio
10.6.6. Pennsylvania
10.6.7. Texas

11. Asia-Pacific Next Generation Cancer Diagnostics Market
11.1. Introduction
11.2. China
11.3. India
11.4. Indonesia
11.5. Japan
11.6. Malaysia
11.7. Philippines
11.8. South Korea
11.9. Thailand

12. Europe, Middle East & Africa Next Generation Cancer Diagnostics Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. Abbott Laboratories
14.2. Adaptive Biotechnologies Inc.
14.3. Agendia Nv
14.4. Agilent Technologies, Inc
14.5. Akadeum Life Sciences
14.6. Almac Group
14.7. Ambry Genetics
14.8. Becton, Dickinson And Co.
14.9. Biological Dynamics Inc.
14.10. Castle Biosciences Inc.
14.11. Danaher Corporation
14.12. Exosome Diagnostics, Inc.
14.13. F. Hoffmann-La Roche Ltd
14.14. GE Healthcare
14.15. Genomic Health, Inc.
14.16. Hologic, Inc
14.17. Illumina, Inc.
14.18. Janssen Global Services, LLC
14.19. Koninklijke Philips N.V.
14.20. Myriad Genetics, Inc.
14.21. Novartis AG
14.22. Opko Health, Inc.
14.23. Perkin Elmer, Inc.
14.24. Qiagen N.V.
14.25. Sysmex Corporation
14.26. Thermo Fisher Scientific, Inc.

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
15.3. Contact Details

List of Tables
TABLE 1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. AMERICAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. AMERICAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. AMERICAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. AMERICAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. AMERICAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. ARGENTINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. ARGENTINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. ARGENTINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. ARGENTINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. BRAZIL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. BRAZIL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. BRAZIL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. BRAZIL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. CANADA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. CANADA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. CANADA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. CANADA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. MEXICO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. MEXICO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. MEXICO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. MEXICO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. CALIFORNIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. CALIFORNIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. CALIFORNIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. CALIFORNIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. FLORIDA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. FLORIDA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. FLORIDA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. FLORIDA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. ILLINOIS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. ILLINOIS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. ILLINOIS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. ILLINOIS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. NEW YORK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. NEW YORK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. NEW YORK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. NEW YORK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. OHIO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. OHIO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. OHIO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. OHIO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. PENNSYLVANIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 73. PENNSYLVANIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 74. PENNSYLVANIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 75. PENNSYLVANIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 76. TEXAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 77. TEXAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 78. TEXAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 79. TEXAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 80. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 81. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 82. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 83. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 84. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 85. CHINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 86. CHINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 87. CHINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 88. CHINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 89. INDIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 90. INDIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 91. INDIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 92. INDIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 93. INDONESIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 94. INDONESIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 95. INDONESIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 96. INDONESIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 97. JAPAN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 98. JAPAN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 99. JAPAN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 100. JAPAN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 101. MALAYSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 102. MALAYSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 103. MALAYSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 104. MALAYSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 105. PHILIPPINES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 106. PHILIPPINES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 107. PHILIPPINES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 108. PHILIPPINES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 109. SOUTH KOREA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 110. SOUTH KOREA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 111. SOUTH KOREA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 112. SOUTH KOREA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 113. THAILAND NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 114. THAILAND NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 115. THAILAND NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 116. THAILAND NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 122. FRANCE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 123. FRANCE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 124. FRANCE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 125. FRANCE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 126. GERMANY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 127. GERMANY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 128. GERMANY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 129. GERMANY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 130. ITALY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 131. ITALY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 132. ITALY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 133. ITALY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 134. NETHERLANDS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 135. NETHERLANDS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 136. NETHERLANDS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 137. NETHERLANDS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 138. QATAR NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 139. QATAR NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 140. QATAR NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 141. QATAR NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 142. RUSSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 143. RUSSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 144. RUSSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 145. RUSSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 146. SAUDI ARABIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 147. SAUDI ARABIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 148. SAUDI ARABIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 149. SAUDI ARABIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 150. SOUTH AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 151. SOUTH AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 152. SOUTH AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 153. SOUTH AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 154. SPAIN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 155. SPAIN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 156. SPAIN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 157. SPAIN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 158. UNITED ARAB EMIRATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 159. UNITED ARAB EMIRATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 160. UNITED ARAB EMIRATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 161. UNITED ARAB EMIRATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 162. UNITED KINGDOM NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 163. UNITED KINGDOM NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 164. UNITED KINGDOM NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 165. UNITED KINGDOM NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 166. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: SCORES
TABLE 167. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: BUSINESS STRATEGY
TABLE 168. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: PRODUCT SATISFACTION
TABLE 169. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: RANKING
TABLE 170. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: MERGER & ACQUISITION
TABLE 171. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 172. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 173. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: INVESTMENT & FUNDING
TABLE 174. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 175. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: LICENSE & PRICING
TABLE 176. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: CONTACT DETAILS
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Adaptive Biotechnologies Inc.
  • Agendia Nv
  • Agilent Technologies, Inc
  • Akadeum Life Sciences
  • Almac Group
  • Ambry Genetics
  • Becton, Dickinson And Co.
  • Biological Dynamics Inc.
  • Castle Biosciences Inc.
  • Danaher Corporation
  • Exosome Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Genomic Health, Inc.
  • Hologic, Inc
  • Illumina, Inc.
  • Janssen Global Services, LLC
  • Koninklijke Philips N.V.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Opko Health, Inc.
  • Perkin Elmer, Inc.
  • Qiagen N.V.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll